The European journal of health economics : HEPAC : health economics in prevention and care
Is next generation sequencing for the diagnosis of rare diseases worth its cost? A user-based approach to valuation.
Karen V MacDonald, Sebastian Heidenreich, Nicolas Krucien, Kym M Boycott, Francois P Bernier, Mandy Ryan, Deborah A Marshall
Published: 202510.1007/s10198-025-01870-8
Abstract
BACKGROUND: Next generation sequencing (NGS) can decrease the diagnostic odyssey for patients with rare diseases. However, valuing the combination of health and non-health outcomes associated with NGS is challenging. While stated preference methods c…
Preview only. Read the full abstract at the source